AVTX- Avalo Therapeutics, Inc.

Insider activity in AVTX over the last quarter tilts toward selling: insiders offloaded a net 101,317 shares worth roughly $2.0M.

Classified under Biotechnology (Health Care sector), AVTX's insider flows are most useful compared with peers in the same group.

Insider Ownership

Role	Insider	Shares	Value	30d
CEO	Neil Garry Arthur	190.3K	-	-
Other	Boyd Taylor	95.0K	-	-
Other	Doyle Mittie	51.8K	$1.04M	-
CFO	Sullivan Christopher Ryan	39.9K	$651.7K	-
Other	Riley Jennifer	37.0K	$725.6K	-

Buys and sells only

10 filings · page 6

Date	Insider	Role	Type	Shares	Price	Value	Chg%	3M	12M
Dec 10, 2021	Neil Garry Arthur	Chief Scientific Officer	Buy	4,267	$1.57	$6,699.19	+5.2%	-61.9%	-76.6%
Dec 10, 2021	Harrell James Archie Jr	Chief Commercial Officer	Buy	1,093	$1.57	$1,716.01	+3.1%	-61.9%	-76.6%
Dec 10, 2021	Sullivan Christopher Ryan	Chief Accounting Officer	Buy	955	$1.57	$1,499.35	+11.9%	-61.9%	-76.6%
Dec 10, 2021	Wilkins H Jeffrey	Chief Medical Officer	Buy	6,371	$1.57	$10,002.47	+23.6%	-61.9%	-76.6%
Dec 10, 2021	Greenway Schond L.	CFO	Buy	2,231	$1.57	$3,502.67	+135.0%	-61.9%	-76.6%
Sep 17, 2021	Armistice Capital, LLC56	Director, 10% Owner	Buy	5,700,000	$2.20	$12,557,901.85	+14.5%	-29.9%	-86.5%
Aug 18, 2021	Armistice Capital, LLC56	Director, 10% Owner	Buy	50,000	$2.76	$138,188.00	+0.1%	-19.8%	-85.3%
Aug 6, 2021	Armistice Capital, LLC56	Director, 10% Owner	Buy	150,000	$2.72	$408,515.00	+0.4%	-16.0%	-88.3%
Jun 10, 2021	Neil Garry Arthur	Chief Scientific Officer	Buy	3,692	$2.28	$8,417.76	+4.8%	-22.9%	-87.0%
Jun 10, 2021	Greenway Schond L.	CFO	Buy	652	$2.68	$1,747.36	+65.2%	-22.9%	-87.0%